Payne becomes RSSL’s investigational partner

Provides support in addressing manufacturer’ problems

RSSL has appointed Philip Payne as its new investigative partner, providing manufacturers of pharmaceuticals, APIs and excipients with support in addressing problems that have led to 'out of specification' test results.

Payne will provide hands-on quality and process improvement support, addressing quality issues within the client's own site and across their supply chain. RSSL can also provide training in topics such as GMP, GDP and quality management, as well as auditing to lead assessor and internal corporate standards.

Payne joined RSSL in 2007 as business development manager and since joining has boosted membership of RSSL's Emergency Response Service, which provides immediate analytical support to manufacturers at a time of a product crisis. He previously worked for Italian API producer Steroid, in a variety of technical roles.

You may also like

Ingredients

Guidance on gluten labelling of pharmaceutical products

This white paper considers the FDA’s guidance on gluten labelling within the pharmaceutical sector, whilst also reflecting on RSSL’s extensive experience and expertise in allergen management and testing
Training & Education

New course in API auditing

Audit of API manufacturing is a key skill requirement for every Qualified Person
Ingredients

Examining excipients

Adulteration of excipients is of growing concern in today’s global supply chain and the US Pharmacopeia has made several changes to protect patients. Philip Payne, investigative partner of testing laboratory RSSL, highlights the latest requirements
Ingredients

Ingredients & integrity

<p>Contamination and counterfeits present a real and growing threat to pharmaceutical companies.<strong> Philip Payne</strong>, RSSL Pharma business development manager, discusses how working with a contract lab can prevent a major product recall or worse disaster</p>
Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

The company will exhibit its omega-3 ingredient, as well as its active gut health solution
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Subscribe now